pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Sep 22·1 min read
save

Novo CEO acknowledges need to rebuild investor confidence after muted capital markets day

Sep 22, 2026·read at Endpoints ↗Negative

Novo held a capital markets day on Monday in London, where the company outlined its strategy. Investors said the presentation left them underwhelmed.

CEO Mike Doustdar acknowledged the reaction, saying the drugmaker must work to rebuild confidence among shareholders and analysts.

The feedback highlights concerns about how Novo is communicating its future plans, and the company may need to refine its messaging to reassure the market.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Novo's CEO knows the drugmaker needs to build confidence”

read at Endpoints ↗
86 words · retrieved Sep 22
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
NOVO6

related stories

  • May 6STAT+: Oregon hospitals won’t outsource to national physician chain after allSTAT
  • May 6STAT+: Color Health moving deeper into cancer services, complete with virtual ‘tumor boards’STAT
  • May 6Novo hikes guidance on Wegovy pill’s fast sales startBioPharma Dive
  • May 6STAT+: How a global effort to explore the ‘dark proteome’ is upending our understanding of human diseaseSTAT
  • May 6STAT+: Novo Nordisk’s less-bad news on its Wegovy pill boosts earnings and share priceSTAT